Alexandre Theocharides

Jun 14, 2023 | frontiersin.org | Alexandre Theocharides |Chengcheng Zhang |Xin Yu

IntroductionImmunotherapies are established as valid therapeutic options in the treatment of cancer (1). Various approaches have been evaluated pre-clinically and individual concepts have been translated into clinical application. Many novel approaches aim to unleash T cell responses in patients. Beside bispecific T cell engagers and chimeric antigen receptor (CAR) T cells, immune checkpoint inhibitors revealed therapeutic efficacy and their approval for clinical use opened up new avenues (2–4).